Breaking: IRIDEX Corporation Has Another Very Weak Trading Session

Breaking: IRIDEX Corporation Has Another Very Weak Trading Session

The stock of IRIDEX Corporation (NASDAQ:IRIX) is a huge mover today! The stock decreased 3.24% or $0.47 during the last trading session, hitting $14.02. About 58,396 shares traded hands or 170.68% up from the average. IRIDEX Corporation (NASDAQ:IRIX) has risen 35.72% since March 1, 2016 and is uptrending. It has outperformed by 23.51% the S&P500.
The move comes after 7 months negative chart setup for the $143.95 million company. It was reported on Oct, 4 by Barchart.com. We have $12.48 PT which if reached, will make NASDAQ:IRIX worth $15.83 million less.

Analysts await IRIDEX Corporation (NASDAQ:IRIX) to report earnings on November, 3.

According to Zacks Investment Research, “IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market.”

Insitutional Activity: The institutional sentiment increased to 5.14 in Q2 2016. Its up 4.32, from 0.82 in 2016Q1. The ratio increased, as 6 funds sold all IRIDEX Corporation shares owned while 1 reduced positions. 22 funds bought stakes while 14 increased positions. They now own 8.59 million shares or 175.70% more from 3.11 million shares in 2016Q1.
Bnp Paribas Arbitrage Sa holds 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX) for 298 shares. Blackrock Institutional Com Na reported 51,248 shares or 0% of all its holdings. Bridgeway Cap Mgmt, a Texas-based fund reported 27,100 shares. Strs Ohio, a Ohio-based fund reported 2,500 shares. Perkins Mngmt has invested 1.37% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). Blackrock Fund Advsr accumulated 198,107 shares or 0% of the stock. Eam Limited has 0.19% invested in the company for 83,683 shares. Morgan Stanley holds 0% or 44,742 shares in its portfolio. Schwab Charles Mgmt accumulated 12,100 shares or 0% of the stock. The California-based California Public Employees Retirement Systems has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Financial Bank Of America De accumulated 142 shares or 0% of the stock. The Pennsylvania-based Federated Inc Pa has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Vanguard Grp last reported 0% of its portfolio in the stock. Acuta Capital Prtn Limited Liability has invested 7.19% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). Wells Fargo Mn has invested 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX).

Insider Transactions: Since May 17, 2016, the stock had 0 insider buys, and 8 sales for $374,428 net activity. 7,896 shares with value of $106,734 were sold by Dizon Romeo R on Thursday, August 18. NAUMANN-ETIENNE RUEDIGER had sold 9,513 shares worth $140,349 on Friday, September 2. $8,448 worth of IRIDEX Corporation (NASDAQ:IRIX) was sold by Steckel Ronald on Monday, June 6. Another trade for 2,513 shares valued at $34,102 was sold by Marcellino George R.

More important recent IRIDEX Corporation (NASDAQ:IRIX) news were published by: Prnewswire.com which released: “IRIDEX Announces Atabak Mokari Will Be Chief Financial Officer And VP …” on July 11, 2016, also Prnewswire.com published article titled: “IRIDEX Announces Cyclo G6â„¢ with MicroPulse® P3 Clinical Data Presented at …”, Prnewswire.com published: “IRIDEX Announces Second Quarter 2016 Conference Call and Release Date” on July 28, 2016. More interesting news about IRIDEX Corporation (NASDAQ:IRIX) was released by: Prnewswire.com and their article: “IRIDEX Gains Patent Approvals Covering TxCellâ„¢-Guided MicroPulse® Laser …” with publication date: March 22, 2016.

IRIX Company Profile

IRIDEX Corporation, incorporated on November 21, 1995, is a well-known provider of therapeutic laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Firm operates through ophthalmology segment. The Company’s ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation. The Company’s ophthalmology products are sold in the United States through a direct sales force and internationally through approximately 70 independent distributors in over 100 countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment